博瑞医药：子公司博瑞制药产品地诺孕素片拟中标全国药品集中采购

Core Viewpoint - The company announced that its wholly-owned subsidiary, Borui Pharmaceutical (Suzhou) Co., Ltd., participated in the national centralized procurement organized by the National Organization for Drug Procurement Office, with its product Dienogest Tablets expected to win the bid [1] Group 1 - Dienogest Tablets received approval from the National Medical Products Administration in December 2024, marking it as a new product for the company [1] - The sales revenue generated from Dienogest Tablets from January to September 2025 amounted to 1.7351 million yuan [1]